BioSante's CML vaccine gains orphan-drug status from FDA

06/7/2010 | International Business Times · Reuters

BioSante Pharmaceuticals said its experimental vaccine GVAX CML was granted orphan-drug designation by the FDA for treating patients with chronic myeloid leukemia. The drugmaker previously obtained orphan status for two other GVAX vaccines to treat pancreatic cancer and acute myeloid leukemia.

View Full Article in:

International Business Times · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA